ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis

ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis

Abstract: Ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor, is the standard of care for symptomatic patients with myelofibrosis (MF). However, ∼70% of patients discontinue ruxolitinib after ∼5 years, a third of whom report suboptimal splenic response. ADORE was a phase 1b/2 study with an innovative...

Full description

Saved in:
Bibliographic Details
Main Authors: David M. Ross, Florian H. Heidel, Andrew Charles Perkins, Andreas Reiter, Carl Crodel, Caroline Riley, María Teresa Gómez-Casares, Istvan Takacs, Heiko Becker, Thomas Lehmann, Olga Vinogradova, Kate Burbury, Alessandro M. Vannucchi, Vikas Gupta, Marielle Wondergem, Jean-Jacques Kiladjian, Grace Cleary, Angela Zhang, Jagannath Kota, Anirudh Prahallad, Monika Wroclawska, Min Lu, Claire N. Harrison
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952925002794
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2473952925002794

Similar Items